Navigation Links
Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
Date:12/9/2012

al development, with the ultimate goal of bringing the right medicines to the right patients to help them live healthier and longer lives. We believe in the value of partnerships that combine our internal scientific expertise with that of industry and academic experts. Our portfolio includes 11 marketed products and more than 15 investigational compounds in clinical development, including small molecules and biological agents.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from
'/>"/>

SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2015)... July 4, 2015 Añadir ... quimioterapia de primera línea para pacientes con cáncer ... extiende la supervivencia libre de progresión en ese ... metastásico no resecable (mCRC) que se ha propagado ... la supervivencia libre de progresión (PFS) en el ...
(Date:7/3/2015)... , July 4, 2015 ... cible les épidémies que sont l,hypertension, le diabète ... du Sud-Est, par l,intermédiaire de plateformes éducatives gratuites ...      (Photo: http://photos.prnewswire.com/prnh/20150630/227090 ) ... charge le diabète en ligne , Prendre ...
(Date:7/3/2015)... 3, 2015 Un fournisseur ... que sont l,hypertension, le diabète et les troubles ... éducatives gratuites et d,une conférence majeure dédiée à ... ) , Les formations ... Prendre en charge l,hypertension en ligne ...
Breaking Medicine Technology:El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 2El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 3El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 4El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 5Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 2Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 3Lutter contre trois maladies chroniques majeures en Amérique latine grâce à la formation médicale 2Lutter contre trois maladies chroniques majeures en Amérique latine grâce à la formation médicale 3
... Codexis, Inc. (Nasdaq: CDXS ) today announced the company ... held in New York, NY on February 23-24, 2011. The presentation ... The company will also present at the Pacific Crest ... March 1-2, 2011. The presentation is scheduled for March 1 at ...
... 8, 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ... subsidiary, Biovail Laboratories International SRL (BLS), has entered into ... (dapsone) Gel 5%, a topical formulation of dapsone used ... will receive from BLS a CA$500,000 upfront payment to ...
Cached Medicine Technology:Valeant Pharmaceuticals Announces License Of ACZONE® (dapsone) Gel 5% In Canada 2Valeant Pharmaceuticals Announces License Of ACZONE® (dapsone) Gel 5% In Canada 3
(Date:7/6/2015)... ... July 06, 2015 , ... “ TapGlance ” was ... the latest and coolest applications on the market for iOS, Android, and Windows. Joe ... with viewers how this interior design app helps users visualize what rooms will look ...
(Date:7/6/2015)... ... July 06, 2015 , ... Acara ... industries, announces the return of its complimentary educational webinar series for ... business leaders creates success for their clients through targeted marketing, sales, digital communications, ...
(Date:7/6/2015)... , ... July 06, 2015 , ... ... reimbursement for radiology services and ADVOCATE is leading the transition. ADVOCATE, the only ... expertise with their Top 10 Tips for ICD-10. The ten tips are timely ...
(Date:7/6/2015)... Aspen, CO (PRWEB) , ... July 06, 2015 , ... ... now, and the ability of the medical field to access and use this “Big ... L. Davis, MD, President and Chief Executive Officer of the Mount Sinai Health System ...
(Date:7/6/2015)... ... July 06, 2015 , ... The School ... funds to support a three-year effort to reduce rates of diabetes and cardiovascular ... in partnership with the Morehouse School of Medicine’s Prevention Research Center and the ...
Breaking Medicine News(10 mins):Health News:Create a Space with TapGlance, a Revolutionary Interior Design Application 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 3Health News:ADVOCATE Takes the Lead to Ensure ICD-10 Success: “Top 10 Tips for ICD-10” 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 3Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 4Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 5Health News:Georgia State, Morehouse Partner To Tackle Diabetes, Heart Disease In Atlanta’s Minority Communities 2
... SMBL ) will hold its annual meeting of ... at the Teaneck Marriott at Glenpointe, 100,Frank W. Burr ... close of business on April 2, 2008, are entitled ... before the meeting., About Smart Balance Inc., ...
... BATESVILLE, Ind., April 25 Hill-Rom Holdings,Inc.,s, (NYSE: ... be,issued Tuesday, May 13, 2008. You are invited to ... 2008 at 8:00 a.m. EDT., Earnings Release: Hill-Rom ... quarter ended March 31, 2008 will be released to,the ...
... for communicating with infants helps ... their little ones better, FLANDERS, N.J., April 25 ... welcome the opportunity to learn,what the future holds. Now they ... The recent highlighting of self-awareness by noteworthy figures on,television and ...
... protein levels could key future treatments for Alzheimer,s , , ... finds that where protein-destroying machines reside in the brain,s ... a finding that may play a role in future ... Wake Forest University School of Medicine researchers studying mice ...
... 25 NutraCea (OTC Bulletin,Board: NTRZ), a world ... technology, today announced that it has entered into,definitive ... aggregate gross proceeds of $20,000,000. The offering is ... that was filed by,NutraCea with the Securities and ...
... CHAPEL HILL, N.C., April 25 Managing multi-generational,diversity ... a recent,benchmarking study with 23 leading companies, 80 ... -- and yet only one-third say,their companies offer ... to download an excerpt of,this new research, ...
Cached Medicine News:Health News:Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2008 Second Quarter Earnings Webcast 2Health News:Internationally Known Psychic Christina Predicts Guides Others to Embrace a More Spiritual Way of Life 2Health News:When It Comes to Memory, It's All About Location 2Health News:NutraCea Announces $20 Million Securities Offering 2Health News:NutraCea Announces $20 Million Securities Offering 3Health News:Multi-generational Diversity Top Challenge for Businesses Today: Leading Company to Share Insights June 4-6 2
PremierEdge™ Stab Knives - 30°....
PremierEdge Stab Knives - 15....
DCR Set, Straight....
... Sonogage CORNEO-GAGE PLUS pachometers are acknowledged ... accurate and measurement-reproducible pachometers available. These benefits ... 50 MHz transducers and smallest tip footprint ... measurement echo average for every displayed reading. ...
Medicine Products: